Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 28 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-4.63 Insider Own10.07% Shs Outstand70.77M Perf Week13.40%
Market Cap1.10B Forward P/E- EPS next Y-3.76 Insider Trans-0.48% Shs Float63.64M Perf Month17.71%
Income-286.25M PEG- EPS next Q-0.85 Inst Own110.18% Short Float22.51% Perf Quarter48.51%
Sales0.00M P/S- EPS this Y16.81% Inst Trans-0.98% Short Ratio17.15 Perf Half Y-39.54%
Book/sh6.82 P/B2.27 EPS next Y-1.18% ROA-51.35% Short Interest14.33M Perf Year-17.39%
Cash/sh7.30 P/C2.12 EPS next 5Y- ROE-62.89% 52W Range9.56 - 31.46 Perf YTD2.24%
Dividend Est.- P/FCF- EPS past 5Y-66.20% ROI-54.52% 52W High-50.76% Beta1.71
Dividend TTM- Quick Ratio8.97 Sales past 5Y-25.00% Gross Margin- 52W Low62.03% ATR (14)1.07
Dividend Ex-Date- Current Ratio8.97 EPS Y/Y TTM1.75% Oper. Margin0.00% RSI (14)68.82 Volatility9.50% 7.25%
Employees156 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin- Recom1.40 Target Price33.56
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q17.88% Payout- Rel Volume2.15 Prev Close14.71
Sales Surprise- EPS Surprise-6.06% Sales Q/Q- EarningsFeb 27 BMO Avg Volume835.22K Price15.49
SMA2024.81% SMA5013.70% SMA200-22.12% Trades Volume1,794,197 Change5.30%
Date Action Analyst Rating Change Price Target Change
Nov-08-23Downgrade Wedbush Outperform → Neutral $38 → $12
Nov-07-23Downgrade Leerink Partners Outperform → Market Perform $15
Jul-12-22Initiated Cowen Outperform
Apr-06-22Initiated Wells Fargo Overweight $67
Oct-07-21Resumed Jefferies Buy $120
Sep-30-21Initiated Stifel Buy $84
Sep-29-21Initiated Oppenheimer Outperform $90
May-21-21Initiated UBS Buy $91
Jan-20-21Initiated Wedbush Outperform $65
Sep-29-20Initiated Cantor Fitzgerald Overweight $44
Today 09:55AM
Feb-27-24 07:01PM
Feb-14-24 09:35AM
07:00AM Loading…
Feb-13-24 07:00AM
Feb-08-24 12:00PM
Feb-05-24 11:26PM
Feb-01-24 05:00PM
Jan-25-24 07:00AM
Jan-08-24 07:00AM
Jan-02-24 04:49PM
Dec-01-23 05:39PM
Nov-13-23 09:03PM
Nov-09-23 07:00AM
07:13PM Loading…
Nov-06-23 07:13PM
Nov-01-23 04:52PM
Oct-07-23 05:00AM
Oct-02-23 04:27PM
Sep-14-23 01:02AM
Sep-06-23 07:00AM
Sep-01-23 04:37PM
Aug-09-23 07:00AM
Aug-01-23 04:28PM
Jun-15-23 06:01AM
Jun-06-23 06:00AM
Jun-02-23 02:34PM
May-26-23 12:33PM
10:53AM Loading…
May-25-23 05:38PM
May-23-23 07:00AM
May-12-23 09:55AM
May-10-23 07:00AM
Apr-26-23 10:00AM
Apr-17-23 09:00AM
Mar-01-23 07:00AM
Feb-13-23 07:00AM
Feb-01-23 05:00PM
Jan-17-23 09:18AM
Jan-03-23 05:00PM
Dec-08-22 09:55AM
Dec-01-22 05:00PM
Nov-09-22 07:00AM
Nov-08-22 07:01AM
Nov-01-22 05:38PM
Oct-24-22 07:00AM
Oct-17-22 07:00AM
Oct-03-22 05:32PM
Sep-27-22 04:01PM
Sep-19-22 07:00AM
Sep-12-22 07:00AM
Sep-01-22 05:00PM
Aug-31-22 07:00AM
Aug-26-22 12:00PM
Aug-16-22 09:55AM
Aug-10-22 04:39PM
Aug-09-22 04:01PM
Aug-03-22 07:00AM
Aug-01-22 05:10PM
Jun-27-22 07:00AM
Jun-14-22 09:10AM
Jun-01-22 07:00AM
May-31-22 07:00AM
May-26-22 09:48AM
May-21-22 09:48AM
May-18-22 04:01PM
May-16-22 07:28AM
May-05-22 07:00AM
Apr-27-22 10:17AM
Apr-19-22 09:35AM
Apr-11-22 04:01PM
Apr-08-22 01:00PM
Mar-29-22 07:00AM
Mar-22-22 07:00AM
Mar-09-22 04:01PM
Mar-08-22 04:30PM
Feb-24-22 07:00AM
Feb-03-22 07:00AM
Dec-22-21 10:15AM
Dec-21-21 12:03PM
Dec-14-21 11:15AM
Dec-02-21 07:00AM
Nov-17-21 11:35AM
Nov-10-21 07:00AM
Nov-09-21 07:00AM
Nov-08-21 10:07AM
Nov-03-21 11:26AM
Oct-25-21 12:04PM
Oct-05-21 11:28AM
Sep-13-21 07:00AM
Sep-09-21 07:00AM
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Epperly Melissa B,Chief Financial OfficerFeb 12Sale11.442,57329,435451,449Feb 12 08:22 PM
Gallagher CamPresidentFeb 12Sale11.441,17313,419643,277Feb 12 08:21 PM
Gallagher CamPresidentFeb 02Sale11.5411,552133,310644,450Feb 05 07:13 PM
Epperly Melissa B,Chief Financial OfficerFeb 02Sale11.548,669100,040454,022Feb 05 07:12 PM
Paul AndreaChief Legal OfficerFeb 02Sale11.543,31038,197149,973Feb 05 07:14 PM
Lackner MarkChief Scientific OfficerFeb 02Sale11.541,58518,291195,728Feb 05 07:15 PM
Blackwell KimberlyChief Executive OfficerNov 13Buy10.295,00051,448254,800Nov 13 05:24 PM
Johnson David MichaelDirectorNov 10Buy9.8817,000167,943144,389Nov 13 05:24 PM
Brownstein CarrieChief Medical OfficerOct 04Sale19.5010,628207,298105,685Oct 06 07:19 PM
Bunker Kevin D.Chief Scientific OfficerOct 04Sale19.506,068118,355859,089Oct 06 07:19 PM
Epperly Melissa B,Chief Financial OfficerOct 04Sale19.505,482106,926387,691Oct 06 07:18 PM
Skvarka JanDirectorSep 11Sale25.055,000125,23847,970Sep 13 04:11 PM
Matrix Capital Management Comp10% OwnerJun 20Buy22.664,760,000107,861,60013,959,973Jun 20 04:30 PM
Gallagher CamPresidentMay 31Sale26.2727,768729,506463,502May 31 09:10 PM
Bunker Kevin D.Chief Scientific OfficerMay 26Sale30.0280,0002,401,24815,000May 31 09:09 PM